On 14 November 2024, Sanofi announced that the European Medicines Agency (EMA) Committee for Medicinal Products for...

On 14 November 2024, Sanofi announced that the European Medicines Agency (EMA) Committee for Medicinal Products for...
On 14 November 2024, Eisai reported that it has received a positive opinion from the European Medicine Agency’s (EMA)...
On 14 November 2024, Merck (known as MSD outside the US and Canada) announced that it has entered an exclusive global...
On 14 November 2024, GlaxoSmithKline (GSK) announced positive results from a planned interim analysis of the DREAMM-7...
On 14 November 2024, UCB announced the presentation of new two-year data from phase 3 studies of Bimzelx®...
GLP-1 agonists (also known as GLP-1 receptor agonists) represent a class of medications used to treat type 2 diabetes...
On 13 November 2024, Alvotech announced its financial results for the first 9 months of 2024, reporting an increase in...
On 13 November 2024, BioNTech announced that it has entered a definitive agreement to acquire Biotheus together with...
On 11 November 2024, Johnson & Johnson (J&J) announced that the US FDA has granted nipocalimab Breakthrough...
On 8 November 2024, Johnson & Johnson (J&J) announced that it has submitted applications to the US FDA and...
On 8 November 2024, Korea Biomedical Review reported that Alteogen has signed an exclusive licence agreement with...
On 8 November 2024, Celltrion announced that it has achieved accumulated sales for Q3 2024 of KRW 2.4 trillion,...
On 7 November 2024, the Galien Foundation awarded Daiichi Sankyo and AstraZeneca the Prix Galien USA Award for Best...
On 6 November 2024, Regeneron and Sanofi announced that the EC, as recommended by CHMP, has approved Dupixent®...
India’s Subject Expert Committee (SEC) has recommended the approval of an additional indication for BMS’ Opdivo®...
Novo Nordisk has reported strong financial performance for the first nine months of 2024. According to a 6 November...